Marketwire - Wholesalers and Distributors

Canexus Announces November Distribution

Fri, 06 Nov 2009 10:21:00 EST

CALGARY, ALBERTA--(Marketwire - Nov. 6, 2009) -�Canexus Income Fund (TSX:CUS.UN) (the "Fund") today announced the cash distribution for the period November 1, 2009, to November 30, 2009, has been set at $0.0456 per unit. The distribution will be paid on December 15, 2009, to unitholders of record as at November 30, 2009. This payment is consistent with the Fund's distribution policy.

The Fund has a Distribution Reinvestment Plan ("DRIP") that enables participants to automatically reinvest monthly distributions in additional trust units of the Fund. More information on the DRIP is available on the Canexus website at www.canexus.ca.�

Agrium Makes Best and Final Offer for CF Industries of $45.00 Per Share in Cash Plus One Agrium Share

Thu, 05 Nov 2009 07:15:00 EST

Urges CF stockholders to send clear message to CF board to accept Agrium's compelling final offer Receives "No-Action" letter from Canadian Competition Bureau and Re-files notification under Hart-Scott-Rodino

Advanced Clean Technologies Retains WorldMarketMedia.com to Design and Implement Their Social Media Marketing Campaign

Wed, 04 Nov 2009 08:00:00 EST

HUNTINGTON BEACH, CA--(Marketwire - November 4, 2009) - Advanced Clean Technologies, Inc. (PINKSHEETS: ACTH) announces the retention of World Market Media, Inc. to lead the Company's Social Media Marketing efforts.

Ronald P. Russo, Jr., Founder & Social Equity Officer, states, "We are delighted that the Advanced Clean Technologies management team has engaged World Market Media to design and implement their Social Media Distribution Plan and Platform."

Agrium Reports Third Quarter Results

Wed, 04 Nov 2009 07:00:00 EST

CALGARY, ALBERTA--(Marketwire - Nov. 4, 2009) - ALL AMOUNTS ARE STATED IN U.S.$ Agrium Inc. (TSX:AGU) (NYSE:AGU) announced today net earnings of $26-million ($0.16 diluted earnings per share) for the third quarter of 2009, compared with the net earnings of $367-million in the third quarter of 2008 ($2.31 diluted earnings per share). The 2009 third quarter results included gains of $5-million ($0.02 diluted earnings per share) on derivative financial instruments and a $25-million expense ($0.11 decrease in diluted earnings per share) in stock-based compensation. It also included an inventory write-down of $9-million (a $0.04 decrease in diluted earnings per share) primarily associated with our Wholesale purchase for resale business. Excluding these items, our net earnings would have been $46-million ($0.29 diluted earnings per share) for the third quarter of 2009.

Alta funcionalidad a su alcance: Las balanzas Serie FZ-i de A&D Weighing

Tue, 03 Nov 2009 13:15:00 EST

SAN JOSE, CA--(Marketwire - November 3, 2009) - A&D Weighing se enorgullece en anunciar la introducci�n de la Serie FZ-i de balanzas de precisi�n, con calibraci�n interna. La FZ-i tiene todas las caracter�sticas de alto rendimiento que los usuarios han llegado a esperar de la Serie FX-i, m�s la adici�n de calibraci�n de un solo paso. Con solo presionar una tecla, usted puede asegurar la precisi�n de su balanza.

Caracter�sticas importantes incluyen:

Advanced Clean Technologies Completes Acquisition of Environmental Remediation Company

Tue, 03 Nov 2009 08:00:00 EST

HUNTINGTON BEACH, CA--(Marketwire - November 3, 2009) - Advanced Clean Technologies, Inc. (PINKSHEETS: ACTH) announced today that it has completed the acquisition of American Petroleum Solutions, Inc., (API), which holds an exclusive license for a patented, oil sludge removal technology. Current ACTH clients already include some of the largest oil and gas companies in the US including ConocoPhillips, ExxonMobil, Avon Petroleum, Valero Petroleum, as well as the US Navy Petroleum Reserve. "This strategic addition to our company, strengthens our offering in the oil and gas industry and accelerates our growth plans," said Russell Kidder, CEO.

Reflect Scientific Consolidates Cryometrix Product Line to Montana Facility

Tue, 03 Nov 2009 06:18:00 EST

OREM, UT--(Marketwire - November 3, 2009) - Reflect Scientific, Inc. (OTCBB: RSCF), a provider of diverse products and services for the biotechnology, pharmaceutical and transportation industries announced the integration of its Cryometrix operation into its Bozeman, Montana facility.

It has been a goal of Reflect Scientific to consolidate product lines to gain economic as well as operational efficiencies where possible. Moving the Cryometrix operation from California to the engineering center in Montana reduces costs by an estimated $900,000 a year and creates a single, more productive engineering group for the company.

DSM delivers strong result improvement in Q3

Tue, 03 Nov 2009 02:08:00 EST

HEERLEN, NETHERLANDS--(Marketwire - November 3, 2009) -

* Q3 operating profit from continuing operations EUR 139 million, more than double Q2 2009 (EUR 58 million)

* Strong Life Sciences performance due to robust Nutrition business

* Materials Sciences continued strong recovery

* Cost savings and efficiency improvements on track to achieve EUR 150 - 200 million on yearly basis by 2010

* Cash flow from operating activities again very strong (Q3 EUR 517 million)

Clorox Announces Plans to Begin Transitioning U.S. Operations to High-Strength Bleach

Mon, 02 Nov 2009 08:29:00 EST

OAKLAND, CA--(Marketwire - November 2, 2009) - The Clorox Company (NYSE: CLX) today announced that it plans to begin modifying manufacturing processes in its U.S. bleach operations. The initiative calls for Clorox to begin transitioning from chlorine to high-strength bleach as a raw material for making its namesake bleach.

"This decision was driven by our commitment to strengthen our operations and add another layer of security," said Chairman and CEO Don Knauss.

Flutiform EU Clinical Trial Successfully Completed

Mon, 02 Nov 2009 05:24:00 EST

LONDON--(Marketwire - November 2, 2009) -


FOR IMMEDIATE RELEASE


SkyePharma Announces Successful Completion of

FlutiformTM EU Clinical Trial Programme


LONDON, UK, 2 November, 2009 - SkyePharma PLC (LSE: SKP) today
announces that its development and marketing partner Mundipharma
International Corporation Limited ("Mundipharma") has successfully
completed the final Phase III clinical study for the European
development programme for FlutiformTM, with the higher dose strength
study (FLT 3503) meeting its primary endpoints. This will enable the
regulatory filing with the European authorities to take place in Q1
2010 as planned.


Study FLT-3503 included 529 patients, who met the requirements for the"per
protocol" analysis, and were suffering from severe, persistent and
reversible asthma. They were treated in an eight week double-blind,
double dummy, randomised multiple centre four arm parallel group study
to assess t